Vasoconstriction compositions and methods of use
AssigneeEye Therapies LLC
InventorGerald HORN
Life of this patent
Estimating the term…
Abstract
The invention generally relates to compositions for inducing vasoconstriction. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.
Claims25
1-13. (canceled)
A method for reducing eye redness in a human subject having ocular hyperemia, consisting of topically administering to an eye of said human in need of said reduction of eye redness a composition in the form of an ocular drop consisting of 0.025% weight by volume brimonidine as the sole active ingredient, and one or more non-therapeutic components wherein the non-therapeutic components do not include a preservative, wherein the ocular drop has a pH between 5.5 to 6.5, and wherein the ocular hyperemia is reduced.
A method for reducing eye redness in a human subject having ocular hyperemia, comprising topically administering to an eye of said human in need of said reduction of eye redness 0.025% weight by volume brimonidine as the sole redness reducing active ingredient, wherein the ocular drop has a pH between 5.5 to 6.5, wherein the ocular drop does not include a preservative, and wherein the ocular hyperemia is reduced.
Dependencies are inferred from the claim text.